Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma

• DOI: 10.1016/j.bcp.2022.115408
• Publication Date: 2023-01-02T01:38:01Z
• Authors: Guillem Pascual-P...; Claudia Resa-Pares; Helena Castillo-E...; Rosario Aschero; Merce Baulenas-Fa...; Monica Vila-Ubach; Victor Burgueño; Leire Balaguer-Lluna; Maria Cuadrado-Vi...; Nagore G. Olaciregui; Nuria Martinez-Ve...; Sara Perez-Jaume; Enrique de Alava; Oscar M. Tirado; Cinzia Lavarino; Jaume Mora; Angel M. Carcaboso
• Keywords: 0301 basic medicine; BiomarkerPatient-derived xenograft (PDX); Paclitaxel; Nanoparticle albumin-bound paclitaxel (nab-paclitaxel); Antineoplastic Agents; Bone Neoplasms; Sarcoma, Ewing; Secreted protein acidic and rich in cysteine (SPARC); 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Ewing sarcomaB-cell lymphoma-2 (Bcl-2); Rhabdomyosarcoma; Humans; Osteonectin; Child; Ensure healthy lives and promote well-being for all at all ages; Biomarkers

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) shows potent preclinical anticancer activity in pediatric solid tumors such as Ewing sarcoma, rhabdomyosarcoma and neuroblastoma, but responses in clinical trials have been modest. In this work, we aimed to discover a rational biomarker-based approach to select the right candidate patients for this treatment. We assessed the efficacy of nab-paclitaxel in 27 patient-derived xenografts (PDX), including 14 Ewing sarcomas, five rhabdomyosarcomas and several other pediatric solid tumors. Response rate (partial or complete response) was remarkable in rhabdomyosarcomas (four of five) and Ewing sarcomas (four of 14). We addressed several predictive factors of response to nab-paclitaxel such as the expression of the secreted protein acidic and rich in cysteine (SPARC), chromosomal stability of cancer cells and expression of antiapoptotic members of the B-cell lymphoma-2 (Bcl-2) family of proteins such as Bcl-2, Bcl-xL, Bcl-W and Mcl-1. Protein (immunoblotting) and gene expression of SPARC correlated positively, while immunoblotting and immunohistochemistry expression of Bcl-2 correlated negatively with the efficacy of nab-paclitaxel in Ewing sarcoma PDX. The negative correlation of Bcl-2 immunoblotting signal and activity was especially robust (r = 0.8352; P = 0.0007; Pearson correlation). Consequently, we evaluated pharmacological strategies to inhibit Bcl-2 during nab-paclitaxel treatment. We observed that the Bcl-2 inhibitor venetoclax improved the activity of nab-paclitaxel in highly resistant Bcl-2-expressing Ewing sarcoma PDX. Overall, our results suggest that low Bcl-2 expression could be used to select patients with Ewing sarcoma sensitive to nab-paclitaxel, and Bcl-2 inhibitors could improve the activity of this drug in Bcl-2-expressing Ewing sarcoma.